Xizhong Cui

Inhaled nitric oxide: is systemic host defense at risk?

Risk and the efficacy of antiinflammatory agents: retrospective and confirmatory studies of sepsis.

Meta-analysis of acute lung injury and acute respiratory distress syndrome trials testing low tidal volumes.

Protection with antibody to tumor necrosis factor differs with similarly lethal Escherichia coli versus Staphylococcus aureus pneumonia in rats.

TGF-beta1 increases microbial clearance but worsens lung injury during Escherichia coli pneumonia in rats.

Lethality during continuous anthrax lethal toxin infusion is associated with circulatory shock but not inflammatory cytokine or nitric oxide release in rats.

Activated protein C in sepsis: emerging insights regarding its mechanism of action and clinical effectiveness.

Severity of sepsis alters the effects of superoxide anion inhibition in a rat sepsis model.

Granulocyte colony-stimulating factor has differing effects comparing intravascular versus extravascular models of sepsis.

Recombinant human activated protein C in sepsis: assessing its clinical use.

Late treatment with a protective antigen-directed monoclonal antibody improves hemodynamic function and survival in a lethal toxin-infused rat model of anthrax sepsis.

Neutrophil inhibition with L-selectin-directed MAb improves or worsens survival dependent on the route but not severity of infection in a rat sepsis model.

Mechanical ventilation in ARDS: One size does not fit all.

Reassessing recombinant human activated protein C for sepsis: time for a new randomized controlled trial.

Neutrophil stimulation with granulocyte colony-stimulating factor worsens ventilator-induced lung injury and mortality in rats.

Antithrombotic therapies for sepsis: a need for more studies.

Effective dosing of lipid A analogue E5564 in rats depends on the timing of treatment and the route of Escherichia coli infection.

Sublethal doses of Bacillus anthracis lethal toxin inhibit inflammation with lipopolysaccharide and Escherichia coli challenge but have opposite effects on survival.

Parthenolide has limited effects on nuclear factor-kappa beta increases and worsens survival in lipopolysaccharide-challenged C57BL/6J mice.

DTPA Fe(III) decreases cytokines and hypotension but worsens survival with Escherichia coli sepsis in rats.

Lethal and edema toxins in the pathogenesis of Bacillus anthracis septic shock: implications for therapy.

Bacillus anthracis edema and lethal toxin have different hemodynamic effects but function together to worsen shock and outcome in a rat model.

Fluid support worsens outcome and negates the benefit of protective antigen-directed monoclonal antibody in a lethal toxin-infused rat Bacillus anthracis shock model.

New insights into the pathogenesis and treatment of anthrax toxin-induced shock.

Neuronal nitric oxide synthase deficiency decreases survival in bacterial peritonitis and sepsis.

Risk of death does not alter the efficacy of hydrocortisone therapy in a mouse E. coli pneumonia model: risk and corticosteroids in sepsis.

Ethyl pyruvate decreased early nuclear factor-kappaB levels but worsened survival in lipopolysaccharide-challenged mice.

Norepinephrine increases blood pressure but not survival with anthrax lethal toxin in rats.

Antithrombosis Trials: Should we test therapeutic heparin adjusted based on activated partial thromboplastin time in septic shock?

The heart is an early target of anthrax lethal toxin in mice: a protective role for neuronal nitric oxide synthase (nNOS).

Can we predict the effects of NF-kappaB inhibition in sepsis? Studies with parthenolide and ethyl pyruvate.

Bacillus anthracis cell wall produces injurious inflammation but paradoxically decreases the lethality of anthrax lethal toxin in a rat model.

Growing insights into the potential benefits and risks of activated protein C administration in sepsis: a review of preclinical and clinical studies.

Risk of death and the efficacy of eritoran tetrasodium (E5564): design considerations for clinical trials of anti-inflammatory agents in sepsis.

Bundled care for septic shock: an analysis of clinical trials.

SB203580, a p38 inhibitor, improved cardiac function but worsened lung injury and survival during Escherichia coli pneumonia in mice.

Anthrax lethal and edema toxins produce different patterns of cardiovascular and renal dysfunction and synergistically decrease survival in canines.

Anthrax edema toxin has cAMP-mediated stimulatory effects and high-dose lethal toxin has depressant effects in an isolated perfused rat heart model.

The effect of heparin administration in animal models of sepsis: a prospective study in Escherichia coli-challenged mice and a systematic review and metaregression analysis of published studies.

Eritoran tetrasodium (E5564) treatment for sepsis: review of preclinical and clinical studies.

Delayed treatment with W1-mAb, a chimpanzee-derived monoclonal antibody against protective antigen, reduces mortality from challenges with anthrax edema or lethal toxin in rats and with anthrax spores in mice.

Disruption of the transient receptor potential vanilloid 1 can affect survival, bacterial clearance, and cytokine gene expression during murine sepsis.

Anthrax infection.

The individual survival benefits of tumor necrosis factor soluble receptor and fluid administration are not additive in a rat sepsis model.

The evolving experience with therapeutic TNF inhibition in sepsis: considering the potential influence of risk of death.

The potential contributions of lethal and edema toxins to the pathogenesis of anthrax associated shock.

Protective antigen antibody augments hemodynamic support in anthrax lethal toxin shock in canines.

An overview of anthrax infection including the recently identified form of disease in injection drug users.

B. anthracis edema toxin increases cAMP levels and inhibits phenylephrine-stimulated contraction in a rat aortic ring model.

Bacillus anthracis cell wall peptidoglycan but not lethal or edema toxins produces changes consistent with disseminated intravascular coagulation in a rat model.

Antitumor necrosis factor therapy is associated with improved survival in clinical sepsis trials: a meta-analysis.

The Surviving Sepsis Campaign's Revised Sepsis Bundles.

B. anthracis associated cardiovascular dysfunction and shock: the potential contribution of both non-toxin and toxin components.

Purified cell wall from the probiotic bacterium Lactobacillus gasseri activates systemic inflammation and, at higher doses, produces lethality in a rat model.

Tidal volume and plateau pressure use for acute lung injury from 2000 to present: a systematic literature review.

Confirmed Bacillus anthracis infection among persons who inject drugs, Scotland, 2009-2010.